StemCells, Inc.
An Huo has extensive experience in quality assurance and control within the pharmaceutical and healthcare sectors. Currently serving as a Sr. Quality Specialist at StemCells, Inc. since March 2015, responsibilities include reviewing batch records, conducting quality control release testing, and leading investigations related to manufactured products. Concurrently, An Huo has held the position of QA Supervisor at Bayer HealthCare Diabetes Care since January 2012, overseeing quality technicians and addressing technical quality issues. In addition to these roles, An Huo has worked as a Bayer News Photographer and as a Sr. Analyst in Quality Control, further showcasing a diverse skill set. Previous experience includes roles at Novartis Vaccines and Diagnostics and Chiron Corporation as an Analyst III. An Huo began a career in laboratory work as a lab technician at the University of California while earning a Bachelor of Sciences in Pharmacology and Pharmacokinetics from UC Santa Barbara.
This person is not in any teams
StemCells, Inc.
StemCells, Inc. is currently engaged in clinical development of its HuCNS-SC® platform technology (purified human neural stem cells) as a potential treatment for both neurological and retinal disorders. Top-line data from the Company's Phase I/II clinical trial in thoracic spinal cord injury (SCI) showed measurable gains involving multiple sensory modalities and segments, including the conversion of two of seven patients enrolled in the study with complete injuries to incomplete injuries, post-transplant. The Company's Pathway™ Study, a Phase II proof-of-concept trial in cervical SCI is actively enrolling at eight sites and interim data from the first cohort of six patients is anticipated to be forthcoming in Q4 2015. StemCells, Inc. has also completed its Phase I/II clinical trial in GA-AMD. Top-line results from this study show a positive safety profile and favorable preliminary efficacy data related to visual acuity and contrast sensitivity. The Company's Radiant™ Study, a Phase II proof-of-concept trial in GA-AMD is now enrolling at the first of approximately twenty U.S. sites expected to participate. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company showed preliminary evidence of progressive and durable donor-derived myelination by MRI.